Viewing Study NCT04643561


Ignite Creation Date: 2025-12-24 @ 1:03 PM
Ignite Modification Date: 2025-12-31 @ 7:04 PM
Study NCT ID: NCT04643561
Status: UNKNOWN
Last Update Posted: 2020-11-27
First Post: 2020-11-24
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Using Travelan to Boost Immune Response in Vitro to COVID-19
Sponsor: Hadassah Medical Organization
Organization:

Study Overview

Official Title: A Feasibility Trial Using Trevalan in Healthy Volunteers for Increasing an in Vitro Immune Response to COVID-19 Proteins
Status: UNKNOWN
Status Verified Date: 2020-11
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The gut immune system was shown as an effective target for inducing systemic immune signals against viruses. Oral administration of Travelan, an over the counter product which contains hyperimmune bovine colostrum was shown in preclinical studies to augment the anti-viral immune towards several strains of influenza viruses (RNA viruses).

This study will evaluate the option that Trevalan may help improve the immune system reaction when introduced to COVID-19 proteins in-vitro. 5 healthy volunteers will receive a treatment regimen of 5 days with Trevalan. Before and after treatment, blood samples will be taken in order to test immune response towards viral proteins of the COVID-19 virus in vitro by measuring the number of T cell clone secreting IFNγ against viral antigens.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: